posted on 2023-03-30, 11:46authored byAnthony DiNatale, Asurayya Worrede, Waleed Iqbal, Michael Marchioli, Allison Toth, Martin Sjöström, Xiaolin Zhu, Eva Corey, Felix Y. Feng, Wanding Zhou, Alessandro Fatatis
Whole genome bisulfite sequencing conducted on a subset of patients with low AR activity and low IL-1β expression revealed 346 CpG sites spanning the IL-1β promoter and gene body on chromosome 2, of which 34 showed significant differences in methylation when comparing patients with similarly low AR activity but having high vs. low expression of IL-1β.
Funding
PA Prostate Cancer Biome Project
HHS | NIH | National Cancer Institute (NCI)
History
ARTICLE ABSTRACT
IL1β plays a crucial role in promoting skeletal metastasis. The current standard of care for patients with prostate cancer inhibits the AR-signaling axis in tumor cells and will consequently unleash IL1β production. Thus, hormonal deprivation and AR inhibitors should be combined with targeting IL1β signaling, and screening for DNA methylation on the IL1β locus will identify patients that benefit the most from this approach.